 EMERYVILLE, Calif., April 22, 2021 GLOBE NEWSWIRE -- Zogenix NASDAQ: ZGNX, a global biopharmaceutical company developing rare disease therapies, today announced new data showing the positive impact of treatment with FINTEPLA fenfluramine oral solution on everyday executive function for children and young adults with Lennox-Gastaut syndrome LGS. FINTEPLA is being investigated for the treatment of seizures associated with LGS, a rare, severe epilepsy that is one of the most challenging developmental and epileptic encephalopathies to manage due to the high seizure frequency and significant neurodevelopmental impairment patients experience. 